Opioids protect against substantia nigra cell degeneration under conditions of iron deprivation: A mechanism of possible relevance to the Restless Legs Syndrome (RLS) and Parkinson's Disease

Journal of the Neurological Sciences

Volumn 304, Issue 1-2, 2011, Pages 93-101

  Sun, Ye Ming J ^a   Hoang, Theresa ^b   Neubauer, Judith A ^b   Walters, Arthur S ^c  

^a University of Medicine and Dentistry of New Jersey   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Desferoxamine; Dopamine; Iron; Opioids; Parkinson's Disease; Restless Legs Syndrome (RLS)

Indexed keywords

CELL DNA; DEFEROXAMINE; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; EPSILON OPIATE RECEPTOR; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL COUNT; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA DETERMINATION; DNA FRAGMENTATION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; IN VITRO STUDY; IRON DEFICIENCY; IRON METABOLISM; MOLECULAR INTERACTION; NERVE CELL CULTURE; NERVE CELL DEGENERATION; NERVE CELL LESION; NERVE CELL NECROSIS; NEUROPATHOLOGY; NEUROPROTECTION; NEWBORN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; RESTLESS LEGS SYNDROME; SUBSTANTIA NIGRA;

ANALGESICS, OPIOID; ANEMIA, IRON-DEFICIENCY; ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; CELL DEATH; CELLS, CULTURED; CYTOPROTECTION; ENKEPHALIN, LEUCINE-2-ALANINE; IRON; IRON CHELATING AGENTS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RESTLESS LEGS SYNDROME; SUBSTANTIA NIGRA;

EID: 79953328053     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2011.02.003     Document Type: Article

References (55)

1. Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 2002;53:547-54.
2. Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 2001;18:128-47. (Pubitemid 32549908)
3. Walters AS. Review of receptor agonist and antagonist studies relevant to the opiate system in restless legs syndrome. Sleep Med 2002;3:301-4.
4. O'Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing 1994;23:200-3. (Pubitemid 24158288)
5. Silber MH, Richardson JW. Multiple blood donations associated with iron deficiency in patients with restless legs syndrome. Mayo Clin Proc 2003;78:52-4. (Pubitemid 36033960)
6. Earley CJ, Heckler D, Allen RP. Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. Sleep Med 2005;6:301-5. (Pubitemid 40867819)
7. Sun ER, Chen CA, Ho G, Earley CJ, Allen RP. Iron and the restless legs syndrome. Sleep 1998;21:371-7. (Pubitemid 128470320)
8. Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurol 2000;54:1698-700. (Pubitemid 30226823)
9. Allen RP, Barker PB, Wehrl F, Song HK, Earley CJ. MRI measurement of brain iron in patients with restless legs syndrome. Neurol 2001;56:263-5. (Pubitemid 32095374)
10. Winkelmann J, Schomair B, Lichtner P, Ripke S, Xiong L, Jalilzadeh S, et al. Genomewide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007;39:1000-6. (Pubitemid 47185185)
11. Stefanson H, Rye DB, Hicks A, Petursson A, Ingason H, Thorgeirsson TE, et al. A genetic risk factor for periodic limb movements in sleep. N Eng J Med 2007;357:639-47. (Pubitemid 47267233)
12. Akpinar S. Restless legs syndrome: treatment with dopaminergic drugs. Clin Neuropharmacol 1987;10:69-79. (Pubitemid 17005659)
13. Winkelmann J, Schadrack J, Wetter TC, Zieglgänsberger W, Trenkwalder C. Opioid and dopamine antagonist drug challenges in untreated restless legs syndrome patients. Sleep Med 2001;2:57-61. (Pubitemid 32184402)
14. Connor JR, Boyer PJ, Menzies SL, Dellinger B, Allen RP, Ondo WG, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurol 2003;61:304-9. (Pubitemid 36975956)
15. Walters AS, Hening W, Cote L, Fahn S. Dominantly inherited restless legs with myoclonus and periodic movements of sleep: a syndrome related to the endogenous opiates? Adv Neurol 1986;43:309-19.
16. Montplaisir J, Lorrain D, Godbout R. Restless legs syndrome and periodic leg movements in sleep: the primary role of dopaminergic mechanism. Eur Neurol 1991;31:41-3.
17. von Spiczak S, Whone AL, Hammers A, Asselin MC, Turkheimer F, Tings T, et al. The role of opioids in restless legs syndrome: an [11 C]diprenorphine PET study. Brain 2005;128:906-17. (Pubitemid 40516927)
18. Walters AS, Ondo WG, Zhu W, Le W. Does the endogenous opiate system play a role in the restless legs syndrome? A pilot post-mortem study. J Neurol Sci 2009;279:62-5.
19. Borlongan CV, Su TP, Wang Y. Treatment with delta opioid peptide enhances in vitro and in vivo survival of rat dopaminergic neurons. NeuroReport 2000;11:923-6. (Pubitemid 30235429)
20. Le NT, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochem Biophys Acta 2002;1603:31-46.
21. Borlongan CV, Su TP, Wang Y. Delta opioid peptide augments functional effects and intrastriatal graft survival of rat fetal ventral mesencephalic cells. Cell Transplant 2001;10:53-8. (Pubitemid 32247070)
22. Borlongan CV, Hayashi T, Oeltgen PR, Su TP, Wang Y. Hibernation-like state induced by an opioid peptide protects against experimental stroke. BMC Biol 2009;7:31.
23. Parka M, Kitahamab K, Geffardc M, Maeda T. Postnatal development of the dopaminergic neurons in the rat mesencephalon. Brain Dev 2000;22:S38-44.
24. Freedman MH, Bentur Y, Koren G. Biological and toxic properties of deferoxamine. Prog Clin Biol Res 1989;309:115-24.
25. Youdim MBH, Yehuda S, Ben Shacker D, Askenazi R. Behavioral and brain biochemical changes in iron deficient rats: the involvement of iron in dopamine receptor function. In: Pollit E, Leibel RL, editors. Iron deficiency: brain biochemistry and behaviour. New York: Raven Press; 1982. p. 39-56.
26. Hayashi T, Tsao LI, Su TP. Antiapoptotic and cytotoxic properties of delta opioid peptide [D-Ala(2),D-Leu(5)]enkephalin in PC12 cells. Synapse 2002;43:86-94.
27. Winkelmann J, Ferini-Strambi L. Genetics of restless legs syndrome. Sleep Med Rev 2006;10:179-83. (Pubitemid 44177434)
28. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18 F-dopa and 11 C-raclopride PET studies. Neurol 1999;52:932-7. (Pubitemid 29161599)
29. Ruottinen HM, Partinen M, Hublin C, Bergman J, Haaparanta M, Solin O, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurol 2000;54:502-4. (Pubitemid 30078095)
30. Trenkwalder C, Walters AS, Hening WA, Chokroverty S, Antonini A, Dhawan V, et al. Positron emission tomographic studies in restless legs syndrome. Mov Disord 1999;14:141-5. (Pubitemid 29224690)
31. Michaud M, Soucy JP, Chabli A, Lavigne G, Montplaisir J. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 2002;249:164-70. (Pubitemid 34143470)
32. Eisensehr I, Wetter TC, Linke R, Noachtar S, von Lindeiner H, Gildehaus FJ, et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurol 2002;59:649-50.
33. Connor JR, Wang XS, Allen RP, Beard JL, Wiesinger JA, Felt BT, et al. Altered dopaminergic profile in the putamen and substantia nigra in restless legs syndrome. Brain 2009;132:2403-12.
34. Allen RP, Connor JR, Hyland K, Earley CJ. Abnormally increased CSF 3-Orthomethyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. Sleep Med 2009;10:123-8.
35. Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, et al. Treatment of the restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008;23:2267-302.
36. Youdim MB, Ben-Shachar D, Yehuda S, Riederer P. The role of iron in the basal ganglion. Adv Neurol 1990;53:155-62.
37. Erikson KM, Jones BC, Hess EJ, Zhang Q, Beard JL. Iron deficiency decreases dopamine D1 and D2 receptors in rat brain. Pharmacol Biochem Behav 2001;69:409-18. (Pubitemid 32758724)
38. Erikson KM, Jones BC, Beard JL. Iron deficiency alters dopamine transporter functioning in rat striatum. J Nutr 2000;130:2831-7.
39. Freye E, Levy JV, Partecke L. Use of gabapentin for attenuation of symptoms following rapid opiate detoxification (ROD) - correlation with neurophysiological parameters. Neurophysiol Clin 2004;34:81-9. (Pubitemid 38586795)
40. Su TP. Delta opioid peptide[D-Ala(2), D-Leu(5)]enkephalin promotes cell survival. J Biomed Sci 2000;7:195-9.
41. Hayashi T, Hirata H, Asanuma M, Ladenheim B, Tsao LI, Cadet JL, et al. Delta opioid peptide [D-Ala2, D-Leu5]enkephalin causes a near complete blockade of the neuronal damage caused by a single high dose of methamphetamine: examining the role of p53. Synapse 2001;39:305-12.
42. Sun Y, Hoang T, Neubauer JA, Walters AS. Apoptotic genes involved in iron deprivation induced substantia nigra cell degeneration and opiate stabilization of the gene expression: further studies on an in vitro model of restless legs syndrome (RLS). Sleep 2006;29:A292-3.
43. Walters AS, Wagner ML, Hening WA, Grasing K, Mills R, Chokroverty S, et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993;16:327-32. (Pubitemid 23176289)
44. Simakajornboon N, Gozal D, Vlasic V, Mack C, Sharon D, McGinley BM. Periodic limb movements in sleep and iron status in children. Sleep 2003;26:735-8. (Pubitemid 39619785)
45. Snyder AM, Connor JR. Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta 2009;1790:606-14.
46. Baier PC, Ondo WG, Winkelmann J. Animal studies in restless legs syndrome. Mov Disord 2007;18:S459-65 22 Supplement.
47. Ondo WG, He Y, Rajasekaran S, Le WD. Clinical correlates of 6-hydroxydopamine injections into A 11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov Disord 2000;15:154-8.
48. Qu S, Le W, Zhang X, Kie W, Zhang A, Ondo WG. Locomotion is increased in a11- lesioned mice with iron deprivation: a possible animal model for restless legs syndrome. J Neuropathol Exp Neurol 2007;66:383-8. (Pubitemid 46701320)
49. Allen RP, Earley CJ. The role of iron in restless legs syndrome. Mov Disord 2007;18: S440-8 22 Supplement.
50. Iwata M, Inoue S, Kawaguchi M, Nakamura M, Konishi N, Furuya H. Effects of delta-opioid receptor stimulation and inhibition on hippocampal survival in a rat model of forebrain ischaemia. Br J Anaesth 2007;99:538-46. (Pubitemid 47412498)
51. Kieffer BL, Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol 2002;66:285-306. (Pubitemid 34518287)
52. Zuckerman A, Bolan E, de Paulis T, Schmidt D, Spector S, Pasternak GW. Pharmacological characterization of morphine-6-sulfate and codeine-6-sulfate. Brain Res 1999;842:1-5.
53. Walters AS, DeAndrade MP, Doroodchi A, Li Y. The Mu opiate receptor knock outmouse shows increased sensitivity to pain, increased motor activity during the sleep period and decreased serum iron parallel to human RLS; 2011. SLEEP (Abstract) submitted.
54. Davies P, Moualla D, Brown DR. Alpha-synuclein is a cellular ferrireductase. PLoS ONE 2011;6:e15814.
55. Deleidi M, Hallett PJ, Koprich JB, Chung CY, Isacson O. The toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. J Neurosci 2010;30:16091-101.